Hengrui Pharmaceutical announced that Chengdu Shengdi Pharmaceutical Co., Ltd., a subsidiary of the company, recently received a notice from the State Drug Administration to approve the marketing of a Class 1 new drug, rikoncopam fumarate capsules, developed independently by the company to treat adult patients with paroxysmal nocturnal hemoglobinuria who have not previously been treated with complement inhibitors.

Hengrui Pharmaceutical announced that Chengdu Shengdi Pharmaceutical Co., Ltd., a subsidiary of the company, recently received a notice from the State Drug Administration to approve the marketing of a Class 1 new drug, rikoncopam fumarate capsules, developed independently by the company to treat adult patients with paroxysmal nocturnal hemoglobinuria who have not previously been treated with complement inhibitors.